ANG Lifesciences India Ltd (ANG) — shareholding pattern, promoter holding, financials and share price
About ANG Lifesciences India Ltd (ANG)
ANG Lifesciences India Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ANG and on the BSE under scrip code 540694. Its ISIN is INE236W01016.
Incorporated in 2006, ANG Lifesciences India Ltd is in the business of pharmaceuticals products & formulations, and packaging and printing. [1]
ANG Lifesciences India Limited specializes in manufacturing and marketing sterile dry powder injection vials, primarily targeting hospitals and doctors through stockists.
The company operates four formulation plants in Baddi, Himachal Pradesh, equipped with advanced technology for producing Beta Lactum and Non-Beta Lactum products.
Listed peers in Pharmaceuticals: Vivimed Labs Ltd, Shelter Pharma Ltd, Vista Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, Rajnish Wellness Ltd, Sandu Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹33.25 a share on 10 Jul 2026, ANG Lifesciences India Ltd (ANG) was valued at a price-to-book of 0.68x on a book value of ₹48.99 per share as of Mar 2025. Solomo computes return on equity of -17.33% and return on capital employed of -3.44% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 36.41x
- P/B
- 0.68x
- EPS (TTM)
- ₹-8.49
- Book value / share
- ₹48.99
- ROE
- -17.33%
- ROCE
- -3.44%
- ROA
- -4.83%
- Debt / equity
- 1.3x
- Dividend yield
- 0%
- EBITDA margin
- 1.34%
- 52-week range
- ₹17.63 – ₹49.69
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, ANG Lifesciences India Ltd (ANG) reported revenue of ₹93 crore, net profit of ₹-11 crore and earnings per share of ₹-8.49. That compares with revenue of ₹93 crore and net profit of ₹-12 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹23.5 crore and net profit ₹-1.38 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 354 | 220 | 145 | 93 | 93 |
| Net profit (₹ cr) | 40 | 0 | -10 | -12 | -11 |
| EPS (₹) | 31.02 | -0.2 | -7.77 | -9.5 | -8.49 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.63% | -6.65% | -36.35% | -36.45% |
| Profit growth | - | - | - | -22.39% |
| Stock price CAGR | - | -17% | -21% | 3% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 70.6% of ANG Lifesciences India Ltd (ANG) (unchanged from the previous quarter). Promoters have pledged 44.9% of their holding. Market capitalisation was ₹43 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2017.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 70.6% | 44.9% | - | - | 29.4% |
| Dec 2025 | 70.6% | 44.9% | - | - | 29.4% |
| Sep 2025 | 70.6% | 44.9% | - | - | 29.4% |
| Jun 2025 | 70.6% | 44.9% | - | - | 29.4% |
| Mar 2025 | 70.6% | 44.9% | - | - | 29.4% |
| Dec 2024 | 70.6% | 44.9% | - | - | 29.4% |
| Sep 2024 | 70.6% | 44.9% | - | - | 29.4% |
| Jun 2024 | 70.6% | 44.9% | - | - | 29.4% |